Risk and outcomes of invasive pneumococcal disease in adults with underlying conditions in the post-PCV7 era, The Netherlands

Vaccine

Volumn 34, Issue 3, 2016, Pages 334-340

  Wagenvoort, Gertjan H J ^a   Knol, Mirjam J ^b   de Melker, Hester E ^b   Vlaminckx, Bart J ^a   van der Ende, Arie ^c   Rozenbaum, Mark H ^d,e   Sanders, Elisabeth A M ^b,f  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d PFIZER INC   (United States)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Clinical outcome; Comorbidity; Invasive pneumococcal disease; Pneumococcal conjugate vaccine; Serotypes; Streptococcus pneumoniae; Surveillance

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; AGED; ARTICLE; COMORBIDITY; FATALITY; FEMALE; GROUPS BY AGE; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; IMMUNOCOMPROMIZED PATIENT; INCIDENCE; INFECTION RISK; INTERMEDIATE RISK POPULATION; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; POPULATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK FACTOR; SEROTYPE; ADOLESCENT; BACTEREMIA; CLASSIFICATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MENINGITIS, BACTERIAL; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PNEUMOCOCCAL INFECTIONS; RISK ASSESSMENT; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; FEMALE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HUMANS; MALE; MENINGITIS, BACTERIAL; MIDDLE AGED; NETHERLANDS; PNEUMOCOCCAL INFECTIONS; RISK ASSESSMENT; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84955335022     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.11.048     Document Type: Article

References (36)

1. van Deursen A.M., van Mens S.P., Sanders E.A., Vlaminckx B.J., de Melker H.E., Schouls L.M., et al. Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, The Netherlands. Emerg Infect Dis 2012, 18(11):1729-1737.
2. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374(9693):893-902.
3. Wroe P.C., Finkelstein J.A., Ray G.T., Linder J.A., Johnson K.M., Rifas-Shiman S., et al. Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis 2012, 205(10):1589-1592.
4. Kyaw M.H., Rose C.E., Fry A.M., Singleton J.A., Moore Z., Zell E.R., et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 2005, 192(3):377-386.
5. Greenberg D., Givon-Lavi N., Ben-Shimol S., Ziv J.B., Dagan R. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 Years. Vaccine 2015, 33(36):4623-4629.
6. Myint T.T., Madhava H., Balmer P., Christopoulou D., Attal S., Menegas D., et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther 2013, 30(2):127-151.
7. Moberley S., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013, 1:CD000422.
8. Knottnerus J.A., van den Bosch W.J.H.M., Claassen E.H.J.H.M., Conyn-van Spaendonck M.A.E., Coutinho R.A., Desmyter J., Hoogkamp-Korstanje J.A.A., et al. Pneumococcal vaccine in elderly adults and risk groups 2003, Health Council of The Netherlands, The Hague, (publication no. 2003/10), ISBN 90-5549-486-0.
9. de Greeff S.C., Sanders E.A., de Melker H.E., van der Ende A., Vermeer P.E., Schouls L.M. Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk. Ned Tijdschr Geneeskd 2007, 151(26):1454-1457.
10. Rozenbaum M.H., Hak E., van der Werf T.S., Postma M.J. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged >or =65 years in The Netherlands. Clin Ther 2010, 32(8):1517-1532.
11. Weil-Olivier C., Gaillat J. Can the success of pneumococcal conjugate vaccines for the prevention of pneumococcal diseases in children be extrapolated to adults?. Vaccine 2014, 32(18):2022-2026.
12. Feikin D.R., Elie C.M., Goetz M.B., Lennox J.L., Carlone G.M., Romero-Steiner S., et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001, 20(3-4):545-553.
13. Bonten M.J., Huijts S.M., Bolkenbaas M., Webber C., Patterson S., Gault S., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015, 372(12):1114-1125.
14. van Hoek A.J., Andrews N., Waight P.A., Stowe J., Gates P., George R., et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012, 65(1):17-24.
15. Shea K.M., Edelsberg J., Weycker D., Farkouh R.A., Strutton D.R., Pelton S.I. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 2014, 1(1):ofu024.
16. Jansen A.G., Rodenburg G.D., van der Ende A., van Alphen L., Veenhoven R.H., Spanjaard L., et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009, 49(2):e23-e29.
17. Rodenburg G.D., de Greeff S.C., Jansen A.G., de Melker H.E., Schouls L.M., Hak E., et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, The Netherlands. Emerg Infect Dis 2010, 16(5):816-823.
18. Knol M.J., Wagenvoort G.H., Sanders E.A., Elberse K., Vlaminckx B.J., de Melker H.E., et al. Invasive pneumococcal disease 3 years after introduction of 10-valent pneumococcal conjugate vaccine, The Netherlands. Emerg Infect Dis 2015, 21(11):2040-2044.
19. Tacken M.A., Braspenning J.C., Berende A., Hak E., De Bakker D.H., Groenewegen P.P., et al. Vaccination of high-risk patients against influenza: impact on primary care contact rates during epidemics. Analysis of routinely collected data. Vaccine 2004, 22(23-24):2985-2992.
20. Tacken M.A., Opstelten W., Vossen I., Smeele I.J., Calsbeek H., Jacobs J.E., et al. Increased multimorbidity in patients in general practice in the period 2003-2009. Ned Tijdschr Geneeskd 2011, 155(26):A3109.
21. Rothman K., Greenland S. Chapter 15 introduction to stratified analysis. Modern Epidemiology 2008, 258-282. Wolters Kluwer, Philadelphia (USA). K. Rothman, S. Greenland (Eds.).
22. Chen X., Mao G., Leng S.X. Frailty syndrome: an overview. Clin Interv Aging 2014, 9:433-441.
23. Macintyre C.R., Ridda I., Gao Z., Moa A.M., McIntyre P.B., Sullivan J.S., et al. A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly. PLoS ONE 2014, 9(4):e94578.
24. Anderson S., Halter J.B., Hazzard W.R., Himmelfarb J., Horne F.M., Kaysen G.A., et al. Prediction, progression, and outcomes of chronic kidney disease in older adults. J Am Soc Nephrol 2009, 20(6):1199-1209.
25. Ritchie N.D., Mitchell T.J., Evans T.J. What is different about serotype 1 pneumococci?. Future Microbiol 2012, 7(1):33-46.
26. Sjostrom K., Spindler C., Ortqvist A., Kalin M., Sandgren A., Kuhlmann-Berenzon S., et al. Clonal and capsular types decide whether pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis 2006, 42(4):451-459.
27. Ladhani S.N., Slack M.P., Andrews N.J., Waight P.A., Borrow R., Miller E. Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales. Emerg Infect Dis 2013, 19(1):61-68.
28. Brueggemann A.B., Peto T.E., Crook D.W., Butler J.C., Kristinsson K.G., Spratt B.G. Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children. J Infect Dis 2004, 190(7):1203-1211.
29. Harboe Z.B., Thomsen R.W., Riis A., Valentiner-Branth P., Christensen J.J., Lambertsen L., et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009, 6(5):e1000081.
30. Albrich W.C., Baughman W., Schmotzer B., Farley M.M. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 2007, 44(12):1569-1576.
31. Borrow R. The evidence for use of pneumococcal conjugate over polysaccharide in children. Hum Vaccin Immunother 2013, 9(6):1385-1386.
32. Waight P.A., Andrews N.J., Ladhani S.N., Sheppard C.L., Slack M.P., Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 2015, 15(5):535-543.
33. Regev-Yochay G., Paran Y., Bishara J., Oren I., Chowers M., Tziba Y., et al. Early impact of PCV7/PCV13 sequential introduction to the national pediatric immunization plan, on adult invasive pneumococcal disease: a nationwide surveillance study. Vaccine 2015, 33(9):1135-1142.
34. Nuorti J.P., Butler J.C., Farley M.M., Harrison L.H., McGeer A., Kolczak M.S., et al. Cigarette smoking and invasive pneumococcal disease, Active Bacterial Core Surveillance Team. N Engl J Med 2000, 342(10):681-689.
35. Van Mens S.P., Van Deursen A.M., Meijvis S.C., Vlaminckx B.J., Sanders E.A., De Melker H.E., et al. Increased incidence of serotype-1 invasive pneumococcal disease in young female adults in The Netherlands. Epidemiol Infect 2014, 142(9):1996-1999.
36. Santos-Eggimann B., Cuenoud P., Spagnoli J., Junod J. Prevalence of frailty in middle-aged and older community-dwelling Europeans living in 10 countries. J Gerontol A Biol Sci Med Sci 2009, 64(6):675-681.